Epidemiological data shows that there are currently more than 100 million diabetic patients in my country, which is the first in the world.
At the same time, 60% of patients have at least one complication.
The burden of disease caused by the treatment of diabetes and its complications is heavy, and there is an urgent need for more clinical tools.
Drugs with better prevention and treatment effectiveness can help solve the current dilemma.
Aiming at the prevention and treatment of diabetes and its complications, the collateral disease theory constructed by Academician Wu Yiling puts forward the viewpoint of treating diabetes from the "spleen" and developed the patented Chinese medicine Jinlida Granules, which adds safe and effective treatment options to the clinic.
On March 27th, the "17th International Symposium on Diabetes Collateral Disease Week kick-off meeting and the 8th Chongqing Collateral Disease Annual Meeting" was successfully held.
The meeting was chaired by Professor Yang Gangyi from the Second Affiliated Hospital of Chongqing Medical University.
Professor Deng Wuquan from the Central Hospital of Chongqing University, Professor Fan Xiaoyun from Chongqing Sixth People’s Hospital served as chairpersons, Professor Chen Qiu from Chengdu University of Traditional Chinese Medicine Affiliated Hospital, Professor Chen Jie from Chongqing Ninth People’s Hospital, and Ren Wei from the First Affiliated Hospital of Chongqing Medical University Professor Zhu Danping from Chongqing Hospital of Traditional Chinese Medicine served as a guest speaker.
He gave an in-depth explanation on the prevention and treatment of diabetes and the clinical application of Jinlida granules guided by collateral disease theory.
The audience brought a wonderful academic feast.
This article organizes the essence of the meeting as follows for readers.
Theoretical advantages, "Tongs the spleen and collaterals, moves the spleen and fluids" is the treatment principle throughout the management of type 2 diabetes
Traditional Chinese medicine has a long history of preventing and treating type 2 diabetes.
Professor Chen Qiu introduced that as early as the Spring and Autumn Period, the "Huang Di Nei Jing" had clearly put forward the name, symptoms and treatment of "diarrhea".
The theoretical system of "collateral disease syndrome treatment" constructed by Academician Wu Yiling traces its origins, inherits and innovates, and puts forward an academic viewpoint on the treatment of diabetic diseases from the "spleen" theory.
In the traditional Chinese medicine system, the spleen is the hub for qi transformation of the five internal organs, covering the functions of the spleen and pancreas.
Pancreatic "sun collateral-microcirculation" disorder is a key factor leading to the structural and functional damage of pancreatic islet β-cells.
Therefore, "tongs the spleen and collaterals, transports the spleen and fluid" has become a consistent treatment principle, which can improve glucose tolerance, reduce the incidence, and is effective at the same time Prevent and treat type 2 diabetes and its vascular and neurological complications.
As an innovative Chinese medicine developed under the guidance of the theory of collateral disease, Jinlida Granules perfectly fits the theory of treating diabetes from the "spleen".
The results of a number of studies have shown that Jinlida Granules has a significant systemic effect in the treatment of type 2 diabetes, with significant clinical efficacy and good safety.
This is mainly reflected in: ①Improve insulin resistance, increase insulin receptors, and reduce glucagon levels.
Improve glucose tolerance, lower blood sugar and glycosylated hemoglobin (HbA1c); ②protect islet tissue, reduce islet β cell apoptosis, protect ultrastructure, and promote insulin expression; ③regulate lipid metabolism disorders, reduce blood lipids, BMI, and improve TCM syndromes and symptoms Clinical symptoms.
On the basis of Jinlida granule "Yunpijin" combined with Tongxinluo capsule "Tongpiluo" treatment, it can further improve the islet microcirculation and reduce systemic vascular complications.
Studies have shown that Tongxinluo Capsule can protect the ultrastructure of islet microvascular endothelium to improve the islet microcirculation and β-cell survival microenvironment; Jinlida Granules combined with Tongxinluo Capsules have been proven to improve endothelial function, inhibit the activation of the RASS system, and increase The number of microvessels in the pancreas and pancreatic islets improves the morphology of blood vessels.
Professor Chen emphasized that Chinese medicine treatment of diabetes can make up for the insufficiency of western medicine in the prevention and treatment of diabetes-related symptoms and microvascular complications.
Integrated Chinese and Western medicine treatment of diabetes will become a new trend in the future to better serve the clinic and benefit more patients.
Combining western medicines such as metformin with Jinlida granules can benefit more diabetic patients
In the current treatment of type 2 diabetes, metformin is the first choice for drug treatment.
If there are no contraindications, it should be included in the overall treatment plan for diabetes.
On the basis of introducing the severe trend of diabetes prevention and treatment in my country, combined with the control goals of type 2 diabetes, Professor Chen Jie gave an in-depth explanation on the reasonable choice of metformin combined with oral drugs.
The combined treatment program can lower blood sugar from different aspects, and has a better effect than metformin alone.
After analyzing the advantages and disadvantages of different combination schemes, Professor Chen pointed out that metformin combined with Jinlida granules (Jinguanidine program) has five major characteristics: synergy, stable hypoglycemia, symptom improvement, vascular benefits, and safety in combination.
The advantage of clinical application is the recommended plan in my country's Type 2 Diabetes Prevention and Treatment Guidelines.
In 2015, an evidence-based study led by academician Tong Xiaolin of the Chinese Academy of Sciences included 192 patients with type 2 diabetes who were treated with metformin for 3 months with poor blood sugar control.
After 12 weeks of combined use of Jinlida granules, the results showed that Jinlida granules The group can further reduce HbA1c by 0.
92%, and at the same time can improve islet function and clinical symptoms, reduce weight, and have good safety; stratified analysis shows that this program is in HbA1c>8.
5%, male, age>60 years old, BMI≤24 The curative effect is better in patients with kg/m2 or disease duration> 5 years.
Professor Chen Jie pointed out that in patients with type 2 diabetes, integrated traditional Chinese and Western medicine can complement each other's strengths and benefit more patients.
Another meta-analysis study showed that compared with single use of western medicine, combined use of Jinlida Granules can significantly reduce fasting blood glucose (FBG), 2-hour postprandial blood glucose (2hPG) and HbA1c in patients with type 2 diabetes, and improve islet function.
Reduce weight, and high safety.
From "regulation" to "ping", Jinlida granules play a multi-pronged role in lowering blood sugar
On the basis of the first two speakers, Professor Ren Wei combined with the pathogenesis of type 2 diabetes to further analyze the mechanism of Jinlida granule in reducing blood sugar.
Professor Ren Wei introduced that the occurrence and development of type 2 diabetes involves many factors, and Jinlida granules mainly improve insulin sensitivity and pancreatic β-cell secretion, while regulating blood sugar hormones to achieve blood sugar regulation.
A series of basic studies have shown that in improving insulin resistance, Jinlida granules can: ①Relieve glycotoxicity and improve insulin resistance; ②Reduce triglyceride levels, reduce the secretion of inflammatory factors in adipocytes, and promote the secretion of adiponectin to improve insulin resistance; ③Improve liver function, reduce liver fat accumulation, and slow down the occurrence and development of non-alcoholic fatty liver.
In terms of protecting pancreatic β-cells, it can: ①repair cell damage, reduce the number of islet β-cell damage and the extent of damage; ②play anti-inflammatory and antioxidant effects, and protect islet cells; ③effectively reduce glucagon mRNA in pancreatic tissue The expression and glucagon levels in the peripheral circulation.
In addition to the above effects, Jinlida Granules can also regulate the level of somatostatin, adrenaline and corticosterone and other blood glucose-increasing hormones to achieve a balance between it and insulin, and exert a systemic effect from "regulation" to "ping", which is effective Lower blood sugar.
Focusing on the elderly, Jinlida particles help individualized management of elderly diabetic patients
With the aging of our country's population, the management of elderly diabetic patients is a key topic of clinical concern.
Professor Zhu Danping introduced the application of Jinlida in this patient population.
Professor Zhu pointed out that elderly diabetic patients have the clinical characteristics of large blood glucose fluctuations, high risk of hypoglycemia, many complications, multi-drug combination, and type 2 diabetes as the main morbid population.
The development of individualized treatment plans can help patients obtain maximum benefits and minimum risks.
In terms of treatment strategies, drugs with a low incidence of hypoglycemia should be preferred, and overly intensive hypoglycemic therapy should be avoided.
Traditional Chinese medicine has the advantages of reducing the risk of hypoglycemia and improving uncomfortable symptoms.
It can better ensure the quality of life of patients and is a good choice for elderly patients.
The above-mentioned RCT stratification analysis led by Academician Tong Xiaolin showed that Jinlida Granules has a better anti-diabetic effect on elderly diabetic patients, at the same time it can also reduce the TCM syndrome score, and significantly improve the symptoms of dry mouth and thirst.
Another study showed that combined use of Jinlida granules on the basis of insulin aspart 30 injection and metformin can improve blood sugar fluctuations, make blood sugar more stable, and do not increase the occurrence of hypoglycemia events.
For patients with prediabetes, a study evaluating the effect of Jinlida granules on the prognosis of elderly patients with coronary heart disease and impaired glucose tolerance showed that Jinlida granules can effectively reduce the incidence of cardiovascular events in patients.
In conclusion, Professor Zhu Danping pointed out that for the special group of elderly type 2 diabetes patients, individualized blood glucose management is very important, including setting individualized blood glucose control goals and individualized drug treatments.
The addition of traditional Chinese medicine is beneficial Better patient management.
With the continuous development of research and the deepening of understanding, the treatment of diabetes with Chinese medicine has been recognized more and more.
With the treatment of diabetes with Chinese medicine written into my country's guidelines, integrated traditional Chinese and Western medicine has become the mainstream strategy for diabetes prevention and treatment.
Based on sufficient evidence-based medical evidence, Jinlida Granules guided by collateral disease theory, as a Chinese patent medicine for diabetes treatment recommended by my country's Type 2 Diabetes Prevention and Control Guidelines, can exert systemic effects on multiple targets and bring multiple benefits to patients.
It is undoubtedly clinical A good weapon for diabetes management.
(Source: China Medical Tribune)
[Disclaimer] This article only represents the author's personal views, and the copyright of its pictures and content belongs to the original owner only.
If you claim the rights and interests of the content, please send a letter or e-mail, and this website will take prompt measures, otherwise this website will not be liable for any disputes related to it.